|
|
 |
|
Total Number of Holdings (excluding cash): 50
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
2,351 |
$2,691,142.68 |
7.95% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
10,655 |
$2,401,850.10 |
7.09% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
19,970 |
$2,388,412.00 |
7.05% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
9,953 |
$2,358,861.00 |
6.96% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
39,646 |
$2,239,206.08 |
6.61% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
82,811 |
$1,341,538.20 |
3.96% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
6,445 |
$1,283,199.50 |
3.79% |
| Cardinal Health, Inc. |
CAH |
14149Y108 |
Pharmaceuticals |
5,394 |
$1,147,141.98 |
3.39% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
44,715 |
$1,149,175.50 |
3.39% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
2,489 |
$1,109,521.53 |
3.28% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
3,185 |
$1,097,439.58 |
3.24% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
8,301 |
$1,041,775.50 |
3.08% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
1,824 |
$1,008,927.36 |
2.98% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
1,582 |
$974,796.76 |
2.88% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
3,746 |
$858,545.74 |
2.53% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
7,659 |
$790,638.57 |
2.33% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
9,431 |
$775,228.20 |
2.29% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
4,093 |
$655,002.79 |
1.93% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
11,505 |
$609,649.95 |
1.80% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
2,944 |
$486,466.56 |
1.44% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
2,380 |
$451,843.00 |
1.33% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
968 |
$451,852.72 |
1.33% |
| PTC Therapeutics, Inc. |
PTCT |
69366J200 |
Biotechnology |
6,099 |
$449,374.32 |
1.33% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
9,379 |
$415,395.91 |
1.23% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
7,071 |
$409,481.61 |
1.21% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
5,601 |
$400,359.48 |
1.18% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
3,954 |
$302,243.76 |
0.89% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
12,227 |
$299,561.50 |
0.88% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
5,708 |
$277,237.56 |
0.82% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
3,624 |
$253,897.44 |
0.75% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
5,651 |
$245,083.87 |
0.72% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
1,811 |
$235,647.32 |
0.70% |
| Catalyst Pharmaceuticals, Inc. |
CPRX |
14888U101 |
Biotechnology |
7,368 |
$230,913.12 |
0.68% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
7,377 |
$225,662.43 |
0.67% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
14,532 |
$213,475.08 |
0.63% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
2,922 |
$214,270.26 |
0.63% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
857 |
$208,490.96 |
0.62% |
| Arcus Biosciences, Inc. |
RCUS |
03969F109 |
Biotechnology |
8,348 |
$197,346.72 |
0.58% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
1,847 |
$195,541.89 |
0.58% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
617 |
$191,115.75 |
0.56% |
| Mirum Pharmaceuticals, Inc. |
MIRM |
604749101 |
Biotechnology |
1,843 |
$175,969.64 |
0.52% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
5,876 |
$170,697.80 |
0.50% |
| Ionis Pharmaceuticals, Inc. |
IONS |
462222100 |
Pharmaceuticals |
2,095 |
$156,245.10 |
0.46% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
6,924 |
$151,220.16 |
0.45% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
511 |
$152,119.59 |
0.45% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
3,174 |
$151,495.02 |
0.45% |
| Arcutis Biotherapeutics, Inc. |
ARQT |
03969K108 |
Biotechnology |
6,305 |
$143,690.95 |
0.42% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
1,862 |
$143,206.42 |
0.42% |
| Supernus Pharmaceuticals, Inc. |
SUPN |
868459108 |
Pharmaceuticals |
3,107 |
$141,865.62 |
0.42% |
| Tarsus Pharmaceuticals, Inc. |
TARS |
87650L103 |
Biotechnology |
2,252 |
$138,610.60 |
0.41% |
| US Dollar |
$USD |
|
Other |
67,723 |
$67,722.95 |
0.20% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|